Aon-D21
Community-acquired Pneumonia
Aptarion Biotech AGPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Community-acquired Pneumonia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Linezolid University Ghent | Phase 4 | BB |
Ap-Pa02 Armata Pharmaceuticals, Inc. | Phase 2 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Denver Health and Hospital Authority | Phase 4 | BB |
Amikacin Asian Institute of Gastroenterology, India | Phase 4 | BB |
Penicillin National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | BB |
View all 26 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →